All In Biotech

Drug Trial Radar · NCT06955728

A Clinical Trial on Safety in Pregnant Women and How Well the Infant is Protected Against RSV-associated Lower Respiratory Tract Infection When the Pregnant Woman Receives the Approved RSV Vaccine Compared to a Placebo.

A Phase-IIIb Individually Randomized, Placebo-controlled Trial on Safety of RSVA/B-preF Vaccine in Pregnant Women and Efficacy Against Severe RSV-associated Lower Respiratory Tract Infection in Infants

Last checked: Nov 19, 2026Latest source record: May 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 13,000 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

13,000

Planned (sponsor's estimate)

Start

Sep 3, 2025

Primary completion

Feb 29, 2028

Study completion Feb 29, 2028

Sponsor

Lead sponsor
University of Witwatersrand, South AfricaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
World Health Organization; Bill and Melinda Gates Foundation
First posted
May 2, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
Female only, from 14 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Respiratory syncytial virus (RSV) is a virus that often affects children during childhood. Even though most cases of RSV are mild, it can cause serious disease and even death - especially in very young babies, babies born too early and those born with heart and lung problems. It is the most common cause for children under 5 years old to be hospitalised. In 2019, there were about 33 million RSV-infections in the lower respiratory tract (in the lungs and below the voice box) of which 3,6 million people were hospitalised and 26,300 passed away in hospital due to RSV. Almost half (50%) of deaths that are caused by RSV, happen in children younger than 6 months old and the majority (more than 95%) of these deaths happen to infants and children in low- and middle-income countries. A way that can help protect babies from becoming infected is through giving vaccines against the germ (RSV) that is targeted for prevention. There are currently no registered vaccines that can be given directly to babies however there is a lot of information available that shows that a vaccine can be safely giving to a mother while she is still pregnant. The mother then produces antibodies (protection cells) that is transferred to the baby before the baby is born, and the baby is protected from getting sick during the first few months of life. One of the vaccines that has been developed (ABRYSVO) has been used in many clinical trials in pregnant moms (and older people) to test if it is safe and will protect young babies and much older people who are all at the highest risk for a severe RSV disease. The vaccine was given to more than 4,000 pregnant women. The results from the study and previous studies showed that the vaccine was safe and the babies had a lower chance of getting severe RSV disease and going to hospital. It showed that the vaccine prevented severe RSV infection in around 80% of babies younger than 90 days, and 70% of babies younger than 6 months. Therefore, the vaccine has been licensed in a few countries around the world (including the United States of America and other high-income countries) which means that pregnant women can receive this vaccine during their pregnancy if they wish to (without being on a clinical trial). It has also been licensed in South Africa but is not yet available in the country for pregnant women to receive. The licensure is also underway in other African countries. However, the results of the previous studies of this vaccine also showed that a slightly higher number of premature babies were born to women who received the vaccine compared to women who did not receive the vaccine. The information received from these studies was however not enough to decide if the earlier births were related to the vaccine or not, and more information is needed - which is one of the main reasons for this study. Importantly, all of the babies who were born earlier were only born a few weeks earlier than expected (around 35 weeks of pregnancy), and all the babies were well and survived. The previous studies on this vaccine happened during the COVID-19 pandemic at which time people were wearing masks and contacting other people less therefore not spreading RSV around as we would normally expect. By doing this study, it will assist the investigators to determine if the vaccine is really as good as it is perceived to be for preventing serious RSV illness in the babies. This RSV vaccine is a very important medical intervention, and it is as important that the effect that this vaccine will have on pregnant women and on the infants born to mothers who receive the vaccine can be measured. It is especially important in African and lower-middle income countries as the vaccine was not tested as much in people living in Africa compared to others. Therefore, the main reason for doing this trial is to see how much value the vaccine can bring to these countries in terms of protecting young babies and infants where many may get a severe infection and be hospitalised. It will also measure if the vaccine does increase the chances of a baby being born earlier than expected. It will only be carried out in the countries after the vaccine has been approved for use by pregnant women (at the right time) as part of their pregnancy care.

Conditions

  • RSV Infections
  • RSV Immunisation
  • Preterm Labour

Interventions

  • VaccineDrug

    The active ingredients in RSVpreF are 2 stabilized RSV prefusion F antigens, in equal amounts from virus subgroups A and B, in a lyophilized dosage form for reconstitution.

  • PlaceboOther

    Placebo matched to vaccine but not containing any active ingredients

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the efficacy of RSVA/B-preF against RSV-A or RSV-B subtype confirmed severe LRTI through to 180 days of age by measuring the first occurrence of RT-PCR confirmed RSV severe LRTITime frame: From infant birth to 180 days of age
  2. Evaluate the safety of RSVA/B-preF in relation to preterm births in women with gestational age (GA) staging Level of Certainty [LOC] 1 to 2B at time of enrolment by measuring the occurrence of preterm births (<37 weeks GA)Time frame: At delivery of the infant

Locations

11 sites in 4 countries. Site status is shown where the registry gives one.

  • Kintampo Health Research Centre

    Kintampo, Bono East, Ghana · Not yet recruiting

  • Dodowa Health Research Centre

    Dodowa, Greater Accra Region, Ghana · Not yet recruiting

  • Kenya Medical Research Institute Wellcome Trust

    Kilifi, Kilifi County, Kenya · Not yet recruiting

  • Kenya Medical Research Institute Centre for Global Health Research

    Kisumu, Nyanza, Kenya · Recruiting

  • Wits RHI Shandukani CRS

    Hillbrow, Gauteng, South Africa · Recruiting

  • VIDA Nkanyezi Research Unit

    Johannesburg, Gauteng, South Africa · Recruiting

  • Setshaba Research Centre

    Soshanguve, Gauteng, South Africa · Recruiting

  • Wits Vaccines & Infectious Diseases Analytics (VIDA) Research unit

    Soweto, Gauteng, South Africa · Recruiting

  • Enhancing Care Foundation

    Durban, KwaZulu-Natal, South Africa · Recruiting

  • MRC Unit on Child and Adolescent Health

    Rondebosch, Western Cape, South Africa · Recruiting

  • MRC Unit The Gambia at London School of Hygiene & Tropical Medicine

    Basse Santa Su, Upper River Division, The Gambia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.